



Agenus to Present at the Jefferies 2018 Global Healthcare Conference in New York, NY

June 6, 2018

LEXINGTON, Mass., June 6, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies¹, announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer at Agenus, will make a presentation and host one-on-one meetings with investors at the Jefferies 2018 Global Healthcare Conference at the Grand Hyatt Hotel, New York, NY.



Details of the presentation are provided below:

Presentation Time and Location: Thursday, Jun 7 at 4:30-4:55 PM EDT in Ballroom to be followed by a breakout session at 5:00-05:25 PM EDT in Uris.

A live audio webcast will be accessible on the "Events & Presentations" section of the Company's investor website at www.agenusbio.com where a replay will also be available following the presentation.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.

About AgenTus Therapeutics, Inc.

Agentus Therapeutics, a subsidiary of Agenus, is a preclinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of breakthrough "living drugs" to advance potential cures for cancer patients. Agentus employs naturally-derived and engineered receptors, specifically T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge human immune effector cells to seek and destroy cancer. Agentus also aims to advance adoptive cell therapy formats which would enable off-the-shelf living drugs. Agentus has locations in Lexington, MA and Cambridge, UK. For more information, please visit www.agentustherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus' upcoming presentation. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:

Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com

¹Through AgenTus Therapeutics, a subsidiary of Agenus